Trial Profile
GRAVITAS-119: A Single-Arm, Open-Label, Phase 1 Study of Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Itacitinib (Primary) ; Ciclosporin; Cyclophosphamide; Methotrexate; Mycophenolate mofetil; Tacrolimus
- Indications Graft-versus-host disease
- Focus Proof of concept; Therapeutic Use
- Acronyms GRAVITAS-119
- Sponsors Incyte Corporation
- 12 Feb 2021 Status changed from recruiting to discontinued(Study terminated by sponsor).
- 08 Dec 2020 Results (n=65) presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 31 Aug 2020 Planned number of patients changed from 85 to 90.